肿瘤细胞治疗研究
英文原题：Advancing Immunotherapy in Chronic Lymphocytic Leukemia.
慢性淋巴细胞白血病（CLL）的治疗已显著从化学免疫治疗转向 Bruton 酪氨酸激酶和 BCL2 抑制剂等靶向治疗。
慢性淋巴细胞白血病（CLL）的治疗已从化学免疫治疗显著转向靶向治疗，例如布鲁顿酪氨酸激酶和 BCL2 抑制剂。尽管取得这些进展，CLL 仍无法治愈，其特征包括免疫失调、治疗耐药和毒性累积。为应对这些挑战，新型免疫治疗策略正在发展；它们从根本上采用不同方法靶向免疫与肿瘤之间的相互作用。这些创新包括新型单克隆抗体、重定向 T 细胞细胞毒性的双特异性抗体、嵌合抗原受体（CAR）T 细胞疗法，以及基于自然杀伤（NK）细胞的平台。通过主动募集细胞毒性，这些策略在高危和治疗耐药情境中显示出希望，尤其适用于标准通路抑制不足以控制疾病的患者。在当前 CLL 研究中，确定这些细胞募集型免疫疗法的最佳用途、毒性管理及联合策略已成为关键优先事项。
The treatment of chronic lymphocytic leukemia (CLL) has significantly shifted from chemoimmunotherapy to targeted therapies like Bruton's tyrosine kinase and BCL2 inhibitors. Despite these advancements, CLL remains an incurable disease characterized by immune dysregulation, therapeutic resistance, and cumulative toxicities. To overcome these challenges, novel immunotherapeutic strategies are emerging as fundamentally different approaches that target immune-tumor interactions. These innovations include novel monoclonal antibodies, bispecific antibodies that redirect T cell cytotoxicity, chimeric antigen receptor (CAR) T-cell therapies, and natural killer (NK) cell-based platforms. By actively engaging cellular cytotoxicity, these approaches show promise in high-risk and treatment-resistant scenarios where standard pathway inhibition is inadequate. Establishing optimal use, toxicity management, and combination strategies for these cell-engaging immunotherapies is now a critical priority in contemporary CLL research.
MEMBER ACCOUNT
登录成功会直接打开下一页。
